BioDiem receives third $1 million milestone for flu vaccine

By Angela McDaniels

Seattle, Nov. 29 - BioDiem Ltd. said it has received a third $1 million milestone payment from Nobilon International as part of a licensing agreement that grants Nobilon the majority of rights to BioDiem's intranasal influenza vaccine.

BioDiem may receive up to $5 million in development milestone payments over the next few years, the company said, in addition to royalties on flu vaccine sales.

The agreement grants global manufacturing rights and marketing rights outside of North America to Nobilon, which will pay for flu vaccine development.

BioDiem retains the right to license out the sales and marketing rights in North America while Japanese rights will be shared.

Nobilon is in preclinical development with the vaccine, which is to be manufactured in cell culture, thereby offering rapid scale-up and efficiency advantages over the traditional egg-based production method, the company said.

Additionally, the intranasal, cold-adapted influenza vaccine technology offers the potential advantage of a broader protection against variant strains of influenza, such as avian flu.

BioDiem is based in Melbourne, Australia, where it works on vaccines, infectious diseases and other therapeutic areas.

Nobilon is a biotechnology company that develop vaccines. It is a subsidiary of Akzo Nobel and is based in Boxmeer, the Netherlands.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.